Vanda Pharmaceuticals Launches NEREUS, First New Motion Sickness Drug in 40 Years
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VNDA?
Source: NASDAQ.COM
- New Drug Launch: Vanda Pharmaceuticals has announced the U.S. commercial launch of NEREUS, marking the first new prescription medicine for motion sickness in over 40 years, expected to meet the needs of approximately 65 to 78 million Americans and significantly improve patient travel experiences.
- Successful Clinical Trials: NEREUS received FDA approval on December 30, 2025, after two pivotal Phase 3 trials demonstrated significant vomiting prevention, enhancing the drug's competitive position in the market.
- Convenient Dosing Regimen: Patients can take one or two capsules about an hour before travel, simplifying the medication process, which is likely to attract more patients and drive sales growth.
- Price Advantage: With a cash-pay price of $85 per dose compared to the standard price of $255, NEREUS offers a significant cost advantage, expected to enhance patient acceptance and market penetration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.100
Low
7.50
Averages
13.63
High
22.00
Current: 7.100
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanda's Nereus Drug Approved by FDA for Motion Sickness
- FDA Approval: Vanda's Nereus drug received FDA approval in December, marking the first new pharmacologic treatment for motion sickness in over 40 years, representing a significant breakthrough for the company in this therapeutic area and likely enhancing its market share.
- Significant Price Advantage: Priced at $85 per dose for cash payments, Nereus offers a substantial discount from the standard list price of $255, which is expected to attract more patients and enhance the company's revenue potential.
- Successful Clinical Trials: Nereus demonstrated significant efficacy in preventing vomiting during two late-stage trials conducted in real-world conditions on the open sea, confirming its effectiveness for motion sickness treatment and laying a solid foundation for future market promotion.
- Market Reaction Analysis: Although VNDA shares rose 4% post-FDA approval, retail sentiment shifted from 'neutral' to 'bearish', indicating market concerns about potential acquisitions by GLP-1 drug manufacturers, reflecting investor interest in the company's future strategic partnerships.
See More
Vanda Pharmaceuticals Launches NEREUS, First New Motion Sickness Drug in 40 Years
- New Drug Launch: Vanda Pharmaceuticals has announced the U.S. commercial launch of NEREUS, marking the first new prescription medicine for motion sickness in over 40 years, expected to meet the needs of approximately 65 to 78 million Americans and significantly improve patient travel experiences.
- Successful Clinical Trials: NEREUS received FDA approval on December 30, 2025, after two pivotal Phase 3 trials demonstrated significant vomiting prevention, enhancing the drug's competitive position in the market.
- Convenient Dosing Regimen: Patients can take one or two capsules about an hour before travel, simplifying the medication process, which is likely to attract more patients and drive sales growth.
- Price Advantage: With a cash-pay price of $85 per dose compared to the standard price of $255, NEREUS offers a significant cost advantage, expected to enhance patient acceptance and market penetration.
See More
Vanda Pharmaceuticals Launches Nereus for Motion Sickness
- New Drug Launch: Vanda Pharmaceuticals announced the launch of Nereus (tradipitant), marking the first new drug for preventing motion-induced vomiting in adults in over 40 years, representing a significant breakthrough in motion sickness treatment.
- Drug Mechanism: As an oral neurokinin-1 (NK-1) receptor antagonist, Nereus offers a novel treatment option that is expected to enhance patients' quality of life and meet the urgent market demand for motion sickness therapies.
- Pricing Strategy: The company stated that cash-paying patients could obtain Nereus for $85 per capsule, a pricing strategy aimed at attracting more patients while generating new revenue streams for the company.
- Market Reaction: Following the announcement of Nereus's availability, Vanda Pharmaceuticals' stock rose approximately 3% in after-hours trading, reflecting the market's positive response and the drug's potential commercial value.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Treatment
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication approved for motion sickness in over 40 years, which is expected to significantly improve the quality of life for tens of millions of patients.
- Direct-to-Consumer Access: NEREUS™ is now available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, a significant discount from the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: NEREUS™ demonstrated significant efficacy in preventing vomiting in two pivotal Phase 3 clinical trials conducted under real-world conditions, confirming its effectiveness for patients experiencing motion sickness during actual sea travel, thus providing a new treatment option.
- Historical Significance: The launch of NEREUS™ addresses a long-standing lack of effective treatments for motion sickness and may have positive implications for military and aerospace sectors, enhancing human adaptability in various motion environments.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Relief
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication for motion sickness in over 40 years, addressing the urgent need of 65 to 78 million American adults for new treatment options.
- Innovative Direct-to-Consumer Platform: NEREUS™ is available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, significantly lower than the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: The drug demonstrated significant efficacy in two pivotal Phase 3 clinical trials, effectively preventing vomiting compared to placebo, confirming its effectiveness in real-world sea travel conditions and marking a major breakthrough in motion sickness treatment.
- Historical Significance: The launch of NEREUS™ not only provides a new treatment option for millions suffering from motion sickness but also has the potential to transform future travel experiences by reducing the impact of motion sickness on military and exploratory activities.
See More
Vanda Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Vanda Pharmaceuticals is set to announce its Q1 2026 financial results on May 6, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call at 4:30 PM ET on the same day, during which management will discuss financial results and other corporate activities, aiming to enhance investor understanding of the company's operations.
- Participation Details: Investors can join the call by dialing 1-888-596-4144 for domestic or 1-646-968-2525 for international participants, using passcode 8051722, ensuring smooth information dissemination.
- Replay Information: A replay of the call will be available starting at 8:30 PM ET on May 6, 2026, until May 13, providing access for those unable to attend live, further enhancing the company's engagement with investors.
See More
Vanda's Nereus Drug Approved by FDA for Motion Sickness
- FDA Approval: Vanda's Nereus drug received FDA approval in December, marking the first new pharmacologic treatment for motion sickness in over 40 years, representing a significant breakthrough for the company in this therapeutic area and likely enhancing its market share.
- Significant Price Advantage: Priced at $85 per dose for cash payments, Nereus offers a substantial discount from the standard list price of $255, which is expected to attract more patients and enhance the company's revenue potential.
- Successful Clinical Trials: Nereus demonstrated significant efficacy in preventing vomiting during two late-stage trials conducted in real-world conditions on the open sea, confirming its effectiveness for motion sickness treatment and laying a solid foundation for future market promotion.
- Market Reaction Analysis: Although VNDA shares rose 4% post-FDA approval, retail sentiment shifted from 'neutral' to 'bearish', indicating market concerns about potential acquisitions by GLP-1 drug manufacturers, reflecting investor interest in the company's future strategic partnerships.
See More
Vanda Pharmaceuticals Launches NEREUS, First New Motion Sickness Drug in 40 Years
- New Drug Launch: Vanda Pharmaceuticals has announced the U.S. commercial launch of NEREUS, marking the first new prescription medicine for motion sickness in over 40 years, expected to meet the needs of approximately 65 to 78 million Americans and significantly improve patient travel experiences.
- Successful Clinical Trials: NEREUS received FDA approval on December 30, 2025, after two pivotal Phase 3 trials demonstrated significant vomiting prevention, enhancing the drug's competitive position in the market.
- Convenient Dosing Regimen: Patients can take one or two capsules about an hour before travel, simplifying the medication process, which is likely to attract more patients and drive sales growth.
- Price Advantage: With a cash-pay price of $85 per dose compared to the standard price of $255, NEREUS offers a significant cost advantage, expected to enhance patient acceptance and market penetration.
See More
Vanda Pharmaceuticals Launches Nereus for Motion Sickness
- New Drug Launch: Vanda Pharmaceuticals announced the launch of Nereus (tradipitant), marking the first new drug for preventing motion-induced vomiting in adults in over 40 years, representing a significant breakthrough in motion sickness treatment.
- Drug Mechanism: As an oral neurokinin-1 (NK-1) receptor antagonist, Nereus offers a novel treatment option that is expected to enhance patients' quality of life and meet the urgent market demand for motion sickness therapies.
- Pricing Strategy: The company stated that cash-paying patients could obtain Nereus for $85 per capsule, a pricing strategy aimed at attracting more patients while generating new revenue streams for the company.
- Market Reaction: Following the announcement of Nereus's availability, Vanda Pharmaceuticals' stock rose approximately 3% in after-hours trading, reflecting the market's positive response and the drug's potential commercial value.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Treatment
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication approved for motion sickness in over 40 years, which is expected to significantly improve the quality of life for tens of millions of patients.
- Direct-to-Consumer Access: NEREUS™ is now available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, a significant discount from the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: NEREUS™ demonstrated significant efficacy in preventing vomiting in two pivotal Phase 3 clinical trials conducted under real-world conditions, confirming its effectiveness for patients experiencing motion sickness during actual sea travel, thus providing a new treatment option.
- Historical Significance: The launch of NEREUS™ addresses a long-standing lack of effective treatments for motion sickness and may have positive implications for military and aerospace sectors, enhancing human adaptability in various motion environments.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Relief
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication for motion sickness in over 40 years, addressing the urgent need of 65 to 78 million American adults for new treatment options.
- Innovative Direct-to-Consumer Platform: NEREUS™ is available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, significantly lower than the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: The drug demonstrated significant efficacy in two pivotal Phase 3 clinical trials, effectively preventing vomiting compared to placebo, confirming its effectiveness in real-world sea travel conditions and marking a major breakthrough in motion sickness treatment.
- Historical Significance: The launch of NEREUS™ not only provides a new treatment option for millions suffering from motion sickness but also has the potential to transform future travel experiences by reducing the impact of motion sickness on military and exploratory activities.
See More
Vanda Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Vanda Pharmaceuticals is set to announce its Q1 2026 financial results on May 6, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call at 4:30 PM ET on the same day, during which management will discuss financial results and other corporate activities, aiming to enhance investor understanding of the company's operations.
- Participation Details: Investors can join the call by dialing 1-888-596-4144 for domestic or 1-646-968-2525 for international participants, using passcode 8051722, ensuring smooth information dissemination.
- Replay Information: A replay of the call will be available starting at 8:30 PM ET on May 6, 2026, until May 13, providing access for those unable to attend live, further enhancing the company's engagement with investors.
See More
